NYSEAMERICAN:OSTX OS Therapies Q4 2025 Earnings Results & Report $1.41 +0.02 (+1.44%) Closing price 04:10 PM EasternExtended Trading$1.42 +0.01 (+0.78%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. OS Therapies reported Q4 2025 earnings on March 31, 2026. The company reported EPS of -$0.41. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 31, 2026TimeBefore Market OpensConference Call7:00 AM ET OS Therapies EPS ResultsActual EPS-$0.41Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AOS Therapies Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Annual Report (10-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Annual report(10-K) OS Therapies Q4 2025 Earnings FAQ Did OS Therapies beat earnings estimates for Q4 2025? OS Therapies (NYSEAMERICAN:OSTX) reported earnings of -$0.41 per share for Q4 2025. The report was announced on Tuesday, March 31, 2026. OS Therapies Earnings HeadlinesRubenstein Public Relations Named Agency of Record for OS TherapiesOctober 8, 2026 | globenewswire.comOS Animal Health Receives USDA Feedback on Regulatory Pathway for OST-HER2 in Canine OsteosarcomaOctober 7, 2026 | marketscreener.comMReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.October 15 at 1:00 AM | Base Camp Trading (Ad)OS Therapies bolsters leadership team amid commercialization pushOctober 5, 2026 | tipranks.comOS Therapies, Inc. Announces Appointment of Kerry Clem as Chief Commercial OfficerOctober 2, 2026 | marketscreener.comMAnalysts Offer Insights on NA Companies: OS Therapies Incorporated (OSTX) and Axalta Coating Systems (AXTA)September 22, 2026 | theglobeandmail.comSee More OS Therapies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OS Therapies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OS Therapies and other key companies, straight to your email. Email Address About OS TherapiesOS Therapies (NYSEAMERICAN:OSTX), Inc. is a clinical-stage biotechnology company focused on developing treatments for osteosarcoma and other solid tumors. The company’s work is directed toward cancer patients who have limited treatment options, with an emphasis on pediatric and young-adult oncology. OS Therapies’ lead investigational product is OST-HER2, an immunotherapy designed to stimulate the immune system to recognize and attack tumors that express the HER2 protein. The therapy is being developed primarily for osteosarcoma, a rare bone cancer, and remains investigational rather than an approved commercial treatment. The company’s activities include clinical development, oncology research and the advancement of additional potential therapies for solid tumors. OS Therapies is headquartered in the United States and has focused its development efforts on addressing significant unmet needs in cancer care.View OS Therapies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureASML Can’t Keep Up With AI Demand—Why That's a Good ThingCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling? Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
